CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the ...

The European Medicines Agency’s human medicines committee has recommended that BeOne Medicines’ Tevimbra (tislelizumab) be ...

But while an improved reputation can be a by-product of patient engagement, it should not be the driving force behind it.

Certara Simcyp Simulator becomes first software platform to receive EMA qualification opinion for PBPK modelling: Radnor, Pennsylvania Tuesday, August 5, 2025, 12:00 Hrs [IST] Cer ...

Discontinuation rates in pediatric trials remain high, reflecting logistical and clinical obstacles. To overcome these hurdles, clinical research organizations can assist - re-thinking pediatric trial ...

The IND clearance allows Hemispherian to proceed with a first-in-human Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of GLIX1 in patients with ...

Detailed price information for 4D Molecular Therapeutics Inc (FDMT-Q) from The Globe and Mail including charting and trades.

ZUG, Switzerland and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

BioNTech SE BNTX +3.21% Get Free Report reported a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, up from a loss of 3.36 euros reported a year ago, compared to beating the consensus ...